Ipigrix solution for injections 5 mg/ml. 1ml. ampoules №10

Description

Ipigrix solution Storage

active substance: ipidacrine;

1 ml of solution (1 ampoule) contains 5 mg or 15 mg of ipidacrine hydrochloride monohydrate (in terms of ipidacrine hydrochloride);

Excipients: dilute hydrochloric acid, water for injections.

Dosage form

Solution for injection.

Ipigrix solution Pharmacotherapeutic group

Anticholinesterase drugs. ATX code N07A A.

Clinical characteristics

Indication

– Diseases of the peripheral nervous system: mono- and polyneuropathy, polyradiculopathy, myasthenia and myasthenic syndrome of various etiologies;

– diseases of the central nervous system (CNS): bulbar paralysis and paresis; recovery period of organic lesions of the CNS, which are accompanied by motor disorders.

Ipigrix solution Contraindication

– Hypersensitivity to ipidacrine or to other components of the drug;

– epilepsy;

– extrapyramidal disorders with hyperkinesis;

– angina, severe bradycardia;

– bronchial asthma;

– vestibular disorders;

– peptic ulcer of the stomach or duodenum in the acute stage;

– mechanical obstruction of the intestines and urinary tract.

Method of application and dosage

Doses and duration of treatment are determined individually depending on the severity of the disease. Ipidacrine solutions containing 5 mg / ml and 15 mg / ml are administered intramuscularly or subcutaneously.

Diseases of the peripheral nervous system.

Mono- and polyneuropathy of different genesis: subcutaneously or intramuscularly administered 5-15 mg 1-2 times a day, the course of treatment – 10-15 days (in severe cases – up to 30 days); then treatment is continued in tablet form.

Myasthenia and myasthenic syndrome: subcutaneously or intramuscularly administered 5-30 mg 1-3 times a day, followed by transition to the tablet form. The general course of treatment is 1-2 months. If necessary, treatment can be repeated several times with a break between courses of 1-2 months.

Diseases of the central nervous system.

Bulbar paralysis and paresis: subcutaneously and intramuscularly administered 5-15 mg 1-2 times a day, the course of treatment – 10-15 days, if possible, switch to tablet form.

Recovery period in organic lesions of the CNS.

Intramuscularly – 10-15 mg 1-2 times a day, the course of treatment – up to 15 days, then if possible – 1-2 times a day.

Adverse reactions

Ipidacrine is well tolerated, side effects are rare (in 6.5% of cases), mild and usually do not occur in all patients.

Cardiac disorders: increased heart rate, decreased heart rate.

From the nervous system: at high doses – dizziness, headache, drowsiness, general weakness, convulsions.

From the respiratory system: increased secretion of bronchi, bronchospasm.

From the digestive system: increased salivation, nausea; when using high doses – vomiting, diarrhea, jaundice, chest pain.

From the skin and subcutaneous tissues: increased sweating; when using high doses – allergic skin reactions (itching, rash).

From the reproductive system: increasing the tone of the uterus.

In case of undesirable side effects, reduce the dose or briefly (for 1-2 days) interrupt the use of the drug. Salivation and decreased heart rate can be reduced by m-cholinoblockers (atropine, etc.).

Overdose

Symptoms: bronchosasm, increased sweating, narrowing of the pupils, nystagmus, increased peristalsis of the gastrointestinal tract, spontaneous defecation and urination, vomiting, jaundice, bradycardia, impaired intracardiac conduction, arrhythmias, hypotension, hypotension, obstruction convulsions, coma, speech disorders, drowsiness, general weakness.

Treatment: use symptomatic therapy, use m-cholinoblockers: atropine, cyclodol, metacin, etc.

Use during pregnancy or breastfeeding.

Ipigrix® increases the tone of the uterus and can cause premature birth, so the use of the drug during pregnancy is contraindicated.

The use of the drug during breastfeeding is contraindicated.